NLSP Fundamental Analysis - NLS PHARMACEUTICS LTD

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to NLSP. NLSP was compared to 195 industry peers in the Pharmaceuticals industry. While NLSP seems to be doing ok healthwise, there are quite some concerns on its profitability. NLSP does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

NLSP had negative earnings in the past year.

NLSP had a negative operating cash flow in the past year.

In the past 5 years NLSP always reported negative net income.

In the past 5 years NLSP always reported negative operating cash flow.

1.2 Ratios

NLSP's Return On Assets of -181.68% is on the low side compared to the rest of the industry. NLSP is outperformed by 89.23% of its industry peers.

Looking at the Return On Equity, with a value of -288.47%, NLSP is doing worse than 74.87% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-181.68%
ROE	-288.47%
ROIC	N/A

ROA(3y)-339.54%

ROA(5y)-292.49%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NLSP so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for NLSP has been increased compared to 1 year ago.

Compared to 5 years ago, NLSP has less shares outstanding

There is no outstanding debt for NLSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

NLSP has an Altman-Z score of -45.12. This is a bad value and indicates that NLSP is not financially healthy and even has some risk of bankruptcy.

NLSP's Altman-Z score of -45.12 is on the low side compared to the rest of the industry. NLSP is outperformed by 90.26% of its industry peers.

There is no outstanding debt for NLSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-45.12

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

NLSP has a Current Ratio of 2.69. This indicates that NLSP is financially healthy and has no problem in meeting its short term obligations.

NLSP has a Current ratio (2.69) which is comparable to the rest of the industry.

A Quick Ratio of 2.69 indicates that NLSP has no problem at all paying its short term obligations.

NLSP has a Quick ratio (2.69) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.69
Quick Ratio	2.69

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NLSP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.00%, which is quite impressive.

EPS 1Y (TTM)77%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%79.24%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y71.88%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NLSP. In the last year negative earnings were reported.

Also next year NLSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NLSP!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NLS PHARMACEUTICS LTD

NASDAQ:NLSP (6/18/2025, 8:12:47 PM)

After market: 2.3503 -0.01 (-0.41%)

2.36

+0.07 (+3.06%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-16 2025-05-16/amc

Earnings (Next)N/A N/A

Inst Owners6.44%

Inst Owner Change0%

Ins Owners27.97%

Ins Owner ChangeN/A

Market Cap8.50M

Analysts43.33

Price TargetN/A

Short Float %5.36%

Short Ratio0.58

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	6.04
P/tB	6.04
EV/EBITDA	N/A

EPS(TTM)-2.93

EYN/A

EPS(NY)-0.46

Fwd EYN/A

FCF(TTM)-1.19

FCFYN/A

OCF(TTM)-1.19

OCFYN/A

SpS0

BVpS0.39

TBVpS0.39

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-181.68%
ROE	-288.47%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-339.54%

ROA(5y)-292.49%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	118.18%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.69
Quick Ratio	2.69
Altman-Z	-45.12

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)39.39%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)77%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%79.24%

EPS Next Y71.88%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y69.2%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y55.89%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y55.93%

OCF growth 3YN/A

OCF growth 5YN/A

NLS PHARMACEUTICS LTD (NLSP) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens